KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Operating Expenses (2019 - 2025)

Royalty Pharma's Operating Expenses history spans 7 years, with the latest figure at $233.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 0.64% year-over-year to $233.6 million; the TTM value through Dec 2025 reached $818.7 million, down 15.7%, while the annual FY2025 figure was $818.7 million, 15.7% down from the prior year.
  • Operating Expenses for Q4 2025 was $233.6 million at Royalty Pharma, up from $182.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.0 billion in Q4 2022 and bottomed at -$190.0 million in Q2 2021.
  • The 5-year median for Operating Expenses is $275.2 million (2021), against an average of $272.1 million.
  • The largest annual shift saw Operating Expenses plummeted 287.02% in 2021 before it skyrocketed 1479.41% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $422.3 million in 2021, then surged by 148.27% to $1.0 billion in 2022, then plummeted by 101.61% to -$16.8 million in 2023, then surged by 1479.41% to $232.1 million in 2024, then increased by 0.64% to $233.6 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Operating Expenses are $233.6 million (Q4 2025), $182.1 million (Q3 2025), and $368.9 million (Q2 2025).